133 related articles for article (PubMed ID: 2784018)
1. Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma.
Marumo K; Muraki J; Ueno M; Tachibana M; Deguchi N; Baba S; Jitsukawa S; Hata M; Tazaki H
Urology; 1989 Mar; 33(3):219-25. PubMed ID: 2784018
[TBL] [Abstract][Full Text] [Related]
2. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of interleukin 2 against renal cell carcinoma: basic study and clinical application.
Marumo K; Ueno M; Muraki J; Tachibana M; Deguchi N; Baba S; Jitsukawa S; Hata M; Tazaki H
Urol Int; 1991; 47 Suppl 1():132-7. PubMed ID: 1949370
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
5. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
6. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
Janssen RA; Buter J; Straatsma E; Heijn AA; Sleijfer DT; de Vries EG; Mulder NH; The TH; de Leij L
Cancer Immunol Immunother; 1993; 36(3):198-204. PubMed ID: 8439981
[TBL] [Abstract][Full Text] [Related]
7. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
Pichert G; Jost LM; Fierz W; Stahel RA
Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
Marumo K; Tazaki H
Prog Clin Biol Res; 1990; 350():263-73. PubMed ID: 2117286
[No Abstract] [Full Text] [Related]
11. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA
Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
14. Variable expression of the interleukin-2 receptor alpha chain and MYC genes in lymphocytes from renal cell carcinoma patients treated with interleukin-2.
Hayat K; Finnegan M; Lee KA; Rees RC; Hancock BW; Goyns MH
Cancer Lett; 1992 Aug; 65(2):173-8. PubMed ID: 1511423
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
17. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
18. [Anti-tumor effects of interleukin 2 against genitourinary cancer--basic study and clinical application].
Marumo K
Hum Cell; 1988 Mar; 1(1):65-70. PubMed ID: 3154016
[TBL] [Abstract][Full Text] [Related]
19. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
20. Immunologic effects of recombinant interferon-gamma in patients with renal cell carcinoma.
Marumo K; Murai M; Deguchi N; Ikeuchi K; Tazaki H
Keio J Med; 1990 Jun; 39(2):97-101. PubMed ID: 2120502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]